Treatment of advanced and recurrent gynecologic cancer.
In 1986 73,400 new cases of invasive gynecologic cancer and 45,000 new cases of in situ carcinoma of the uterine cervix (about 9% of all cancers in women) were diagnosed in the US. A significant proportion of these patients die of local failure. In dealing with the wide variety of gynecologic cancers, extreme care must be used in choosing the appropriate treatment program for each problem. Therefore, the full extent of the disease at the time of initial presentation and recurrence must be determined. It is only with these data that appropriate treatment programs can be designed with the maximum potential for long-term control or cure and with the minimum in treatment complication. There are no groups of disease processes like those seen in advanced or recurrent gynecologic cancer that offer such a challenge to the clinical practitioner.
Brady
L W
LW
Department of Radiation Oncology, Hahnemann University, Philadelphia, Pennsylvania 19104.
Markoe
A M
AM
DeEulis
T
T
Lewis
G C
GC
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000628:therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy; D011897:Random Allocation; D002583:Uterine Cervical Neoplasms / Q000628:therapy; D014594:Uterine Neoplasms / Q000628:therapy